Cargando…

National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management

On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO decl...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicastri, Emanuele, Petrosillo, Nicola, Ascoli Bartoli, Tommaso, Lepore, Luciana, Mondi, Annalisa, Palmieri, Fabrizio, D’Offizi, Gianpiero, Marchioni, Luisa, Murachelli, Silvia, Ippolito, Giuseppe, Antinori, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097833/
https://www.ncbi.nlm.nih.gov/pubmed/32218915
http://dx.doi.org/10.4081/idr.2020.8543
_version_ 1783511061243101184
author Nicastri, Emanuele
Petrosillo, Nicola
Ascoli Bartoli, Tommaso
Lepore, Luciana
Mondi, Annalisa
Palmieri, Fabrizio
D’Offizi, Gianpiero
Marchioni, Luisa
Murachelli, Silvia
Ippolito, Giuseppe
Antinori, Andrea
author_facet Nicastri, Emanuele
Petrosillo, Nicola
Ascoli Bartoli, Tommaso
Lepore, Luciana
Mondi, Annalisa
Palmieri, Fabrizio
D’Offizi, Gianpiero
Marchioni, Luisa
Murachelli, Silvia
Ippolito, Giuseppe
Antinori, Andrea
author_sort Nicastri, Emanuele
collection PubMed
description On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data.
format Online
Article
Text
id pubmed-7097833
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-70978332020-03-26 National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management Nicastri, Emanuele Petrosillo, Nicola Ascoli Bartoli, Tommaso Lepore, Luciana Mondi, Annalisa Palmieri, Fabrizio D’Offizi, Gianpiero Marchioni, Luisa Murachelli, Silvia Ippolito, Giuseppe Antinori, Andrea Infect Dis Rep Expert Opinion On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data. PAGEPress Publications, Pavia, Italy 2020-03-16 /pmc/articles/PMC7097833/ /pubmed/32218915 http://dx.doi.org/10.4081/idr.2020.8543 Text en ©Copyright: the Author(s), 2020 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Expert Opinion
Nicastri, Emanuele
Petrosillo, Nicola
Ascoli Bartoli, Tommaso
Lepore, Luciana
Mondi, Annalisa
Palmieri, Fabrizio
D’Offizi, Gianpiero
Marchioni, Luisa
Murachelli, Silvia
Ippolito, Giuseppe
Antinori, Andrea
National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
title National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
title_full National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
title_fullStr National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
title_full_unstemmed National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
title_short National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
title_sort national institute for the infectious diseases “l. spallanzani”, irccs. recommendations for covid-19 clinical management
topic Expert Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097833/
https://www.ncbi.nlm.nih.gov/pubmed/32218915
http://dx.doi.org/10.4081/idr.2020.8543
work_keys_str_mv AT nicastriemanuele nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT petrosillonicola nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT ascolibartolitommaso nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT leporeluciana nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT mondiannalisa nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT palmierifabrizio nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT doffizigianpiero nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT marchioniluisa nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT murachellisilvia nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT ippolitogiuseppe nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement
AT antinoriandrea nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement